EQT Corporation (NYSE:EQT) shares moved down -3.03% in last trading session and ended the day at $56.28. EQT Gross Margin is 84.50% and its has a return on assets of 1.60%. EQT Corporation (NYSE:EQT) quarterly performance is -17.59%.
EQT Corporation (NYSE: EQT) declared a quarterly cash dividend of $0.03 per share, payable March 1, 2016, to shareholders of record at the close of business on February 17, 2016.
Banco Bradesco S.A. (NYSE:BBD) ended the last trading day at $4.12. Company weekly volatility is calculated as 3.61%. Banco Bradesco S.A. (NYSE:BBD) showed a weekly performance of -2.37%.
Banco Bradesco S.A., (NYSE:BBD) in conformity with the System for Payment of Monthly Interest on Shareholders’ Equity, will pay on March 1, 2016 monthly interest on shareholders’ equity related to the month of February/2016, in the amount of R$0.017249826 per common share and R$0.018974809 per preferred share to the shareholders registered in the Company’s records on February 1, 2016 (declaration date and record date of right). The Company’s shares will be traded “ex-right” on interest from February 2, 2016 on.
On 25 January, Aflac Incorporated (NYSE:AFL) shares decreased -1.26% and was closed at $56.55. AFL EPS growth in last 5 year was 15.30%. Aflac Incorporated (NYSE:AFL) year to date (YTD) performance is -5.59%.
Aflac Incorporated (NYSE:AFL) announced that it will release fourth quarter financial results after the market closes on February 1, 2016. In conjunction with the earnings release, Aflac Incorporated will webcast a conference call scheduled for 9:00 a.m. (EST) on February 2, 2016.
Baylake Corp. (NASDAQ:BYLK) shares decreased -0.48% in last trading session and ended the day at $14.43. BYLK has a return on assets of 0.90%. Baylake Corp. (NASDAQ:BYLK) quarterly performance is -0.07%.
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) caters to the Healthcare space. Its On the last day of trading company shares ended up at $1.65. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) distance from 50-day simple moving average (SMA50) is -40.75%.
Brean Capital reaffirmed their buy rating on shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) in a research note released on Thursday morning, Analyst Ratings.Net reports. They currently have a $13.00 price objective on the biotechnology company’s stock.
Leave a Reply